Abstract
New designer drugs (synthetic cannabinoids and synthetic cathinones) are new “legal highs” that are sold online for recreational public or private use.
Synthetic cannabinoids are psychoactive herbal and chemical products that mimic the effects of cannabis when used. These drugs are available on the Internet or in head shops as incense or air fresheners to circumvent the law.
Cathinone is a naturally occurring beta-ketone amphetamine analog found in the leaves of the Catha edulis plant. Synthetic cathinones are phenylalkylamine derivatives that may possess amphetamine-like properties. These drugs are sold online as bath salts.
Designer drugs are often labeled as “not for human consumption” to circumvent drug abuse legislation. The absence of legal risks, the ease of obtaining these drugs, the moderate cost, and the availability via the Internet are the main features that attract users, but the number of intoxicated people presenting with emergencies is increasing.
There is evidence that negative health and social consequences may affect recreational and chronic users. The addictive potential of designer drugs is not negligible.
Keywords: Synthetic cannabinoids, synthetic cathinones, legal highs, recreative drugs.
Current Pharmaceutical Design
Title:New Designer Drugs (Synthetic Cannabinoids and Synthetic Cathinones): Review of Literature
Volume: 20 Issue: 25
Author(s): Olivier Cottencin, Benjamin Rolland and Laurent Karila
Affiliation:
Keywords: Synthetic cannabinoids, synthetic cathinones, legal highs, recreative drugs.
Abstract: New designer drugs (synthetic cannabinoids and synthetic cathinones) are new “legal highs” that are sold online for recreational public or private use.
Synthetic cannabinoids are psychoactive herbal and chemical products that mimic the effects of cannabis when used. These drugs are available on the Internet or in head shops as incense or air fresheners to circumvent the law.
Cathinone is a naturally occurring beta-ketone amphetamine analog found in the leaves of the Catha edulis plant. Synthetic cathinones are phenylalkylamine derivatives that may possess amphetamine-like properties. These drugs are sold online as bath salts.
Designer drugs are often labeled as “not for human consumption” to circumvent drug abuse legislation. The absence of legal risks, the ease of obtaining these drugs, the moderate cost, and the availability via the Internet are the main features that attract users, but the number of intoxicated people presenting with emergencies is increasing.
There is evidence that negative health and social consequences may affect recreational and chronic users. The addictive potential of designer drugs is not negligible.
Export Options
About this article
Cite this article as:
Cottencin Olivier, Rolland Benjamin and Karila Laurent, New Designer Drugs (Synthetic Cannabinoids and Synthetic Cathinones): Review of Literature, Current Pharmaceutical Design 2014; 20 (25) . https://dx.doi.org/10.2174/13816128113199990622
DOI https://dx.doi.org/10.2174/13816128113199990622 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of microRNAs in Vascular Remodeling
Current Molecular Medicine Emerging Therapies for Diabetic Neuropathy: A Clinical Overview
Current Diabetes Reviews Vascular and Parenchymal Mechanisms in Multiple Drug Resistance: a Lesson from Human Epilepsy
Current Drug Targets Long-Term Extensions of Randomized Vaccination Trials of ACC-001 and QS-21 in Mild to Moderate Alzheimer’s Disease
Current Alzheimer Research Underlying Mechanisms and Potential Therapeutic Molecular Targets in Blood-Brain Barrier Disruption after Subarachnoid Hemorrhage
Current Neuropharmacology The Small Bowel: An Imaging Guide
Current Medical Imaging MMP-2 Selectivity in Hydroxamate-Type Inhibitors
Current Medicinal Chemistry NLRP3 Inflammasome in the Pathophysiology of Hemorrhagic Stroke: A Review
Current Neuropharmacology The Effect of Anti-B-cell Therapy on the Development of Atherosclerosis in Patients with Rheumatoid Arthritis
Current Pharmaceutical Design The Role of Oxidative Stress in Smoking-Related Diseases
Mini-Reviews in Organic Chemistry Intravitreal Bevacizumab (Avastin®) for Diabetic Retinopathy at 24-months: The 2008 Juan Verdaguer-Planas Lecture
Current Diabetes Reviews Biochemical Markers of Cardiovascular Damage from Tobacco Smoke
Current Pharmaceutical Design Susceptibility Genes in Hypertension
Current Pharmaceutical Design Neuroprotective Strategies for Neurological Disorders by Natural Products: An update
Current Neuropharmacology The Role of Disproportionality Analysis of Pharmacovigilance Databases in Safety Regulatory Actions: a Systematic Review
Current Drug Safety A Variant in the Endoglin Gene is Associated with the Development of Sporadic Intracranial Aneurysms
Current Neurovascular Research Homocysteine and Non-Cardiac Vascular Disease
Current Pharmaceutical Design Colloid Update
Current Pharmaceutical Design Importance of Receptor-targeted Systems in the Battle Against Atherosclerosis
Current Pharmaceutical Design Basilar Apex Aneurysms in the Setting of Carotid Artery Stenosis: Case Series and Angiographic Anatomic Study
Current Neurovascular Research